BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1128 related articles for article (PubMed ID: 33932067)

  • 1. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Gauthier J; Hirayama AV; Purushe J; Hay KA; Lymp J; Li DH; Yeung CCS; Sheih A; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Shadman M; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2020 May; 135(19):1650-1660. PubMed ID: 32076701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
    Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
    Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
    Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
    J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
    Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
    Mu J; Liu M; Wang J; Meng J; Zhang R; Jiang Y; Deng Q
    Adv Clin Exp Med; 2022 Mar; 31(3):327-335. PubMed ID: 35148570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
    Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
    Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
    J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
    Minson A; Hamad N; Cheah CY; Tam C; Blombery P; Westerman D; Ritchie D; Morgan H; Holzwart N; Lade S; Anderson MA; Khot A; Seymour JF; Robertson M; Caldwell I; Ryland G; Saghebi J; Sabahi Z; Xie J; Koldej R; Dickinson M
    Blood; 2024 Feb; 143(8):673-684. PubMed ID: 37883795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
    Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
    Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with
    Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
    Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
    Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
    J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.